These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 29732998)

  • 1. An Overview of Targeted Alpha Therapy with
    Morgenstern A; Apostolidis C; Kratochwil C; Sathekge M; Krolicki L; Bruchertseifer F
    Curr Radiopharm; 2018; 11(3):200-208. PubMed ID: 29732998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Evolving Clinical Role of Actinium-225 and Bismuth-213 for Targeted Alpha Therapy (TAT) - Production, Radiopharmaceutical Development and Clinical Applications.
    Radchenko V; Schaffer P; Knapp FFR
    Curr Radiopharm; 2018; 11(3):154-155. PubMed ID: 30378473
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies.
    Jurcic JG
    Curr Radiopharm; 2018; 11(3):192-199. PubMed ID: 29793418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of
    Robertson AKH; Ramogida CF; Schaffer P; Radchenko V
    Curr Radiopharm; 2018; 11(3):156-172. PubMed ID: 29658444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NorthStar Perspectives for Actinium-225 Production at Commercial Scale.
    Harvey JT
    Curr Radiopharm; 2018; 11(3):180-191. PubMed ID: 29766832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demand.
    Bruchertseifer F; Kellerbauer A; Malmbeck R; Morgenstern A
    J Labelled Comp Radiopharm; 2019 Sep; 62(11):794-802. PubMed ID: 31369165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted alpha therapy with 213Bi.
    Morgenstern A; Bruchertseifer F; Apostolidis C
    Curr Radiopharm; 2011 Oct; 4(4):295-305. PubMed ID: 22202152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Production of Ac-225.
    Engle JW
    Curr Radiopharm; 2018; 11(3):173-179. PubMed ID: 29669509
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Pfannkuchen N; Bausbacher N; Pektor S; Miederer M; Rosch F
    Curr Radiopharm; 2018; 11(3):223-230. PubMed ID: 29866026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efforts to control the errant products of a targeted in vivo generator.
    Jaggi JS; Kappel BJ; McDevitt MR; Sgouros G; Flombaum CD; Cabassa C; Scheinberg DA
    Cancer Res; 2005 Jun; 65(11):4888-95. PubMed ID: 15930310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Targeted Alpha Therapy from Bench to Bedside.
    Morgenstern A; Bruchertseifer F
    J Med Imaging Radiat Sci; 2019 Dec; 50(4S1):S18-S20. PubMed ID: 31405818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators.
    Kozempel J; Mokhodoeva O; Vlk M
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29510568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retention studies of recoiling daughter nuclides of 225Ac in polymer vesicles.
    Wang G; de Kruijff RM; Rol A; Thijssen L; Mendes E; Morgenstern A; Bruchertseifer F; Stuart MC; Wolterbeek HT; Denkova AG
    Appl Radiat Isot; 2014 Feb; 85():45-53. PubMed ID: 24374072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes.
    Morgenstern A; Bruchertseifer F; Apostolidis C
    Curr Radiopharm; 2012 Jul; 5(3):221-7. PubMed ID: 22642390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary evaluation of alpha-emitting radioembolization in animal models of hepatocellular carcinoma.
    Du Y; Cortez A; Josefsson A; Zarisfi M; Krimins R; Liapi E; Nedrow JR
    PLoS One; 2022; 17(1):e0261982. PubMed ID: 35061763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Actinium-225 in targeted alpha-particle therapeutic applications.
    Scheinberg DA; McDevitt MR
    Curr Radiopharm; 2011 Oct; 4(4):306-20. PubMed ID: 22202153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer.
    Schatz CA; Zitzmann-Kolbe S; Moen I; Klotz M; Nair S; Stargard S; Bjerke RM; Wickstrøm Biseth K; Feng YZ; Indrevoll B; Cruciani V; Karlsson J; Haendler B; Nielsen CH; Alfsen MZ; Hammer S; Hennekes H; Cuthbertson A; Hagemann UB; Larsen Å
    Clin Cancer Res; 2024 Jun; 30(11):2531-2544. PubMed ID: 38593212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.
    Song H; Hobbs RF; Vajravelu R; Huso DL; Esaias C; Apostolidis C; Morgenstern A; Sgouros G
    Cancer Res; 2009 Dec; 69(23):8941-8. PubMed ID: 19920193
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Jiang Z; Revskaya E; Fisher DR; Dadachova E
    Curr Radiopharm; 2018; 11(3):215-222. PubMed ID: 29683101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breakthrough of 225Ac and its radionuclide daughters from an 225Ac/213Bi generator: development of new methods, quantitative characterization, and implications for clinical use.
    Ma D; McDevitt MR; Finn RD; Scheinberg DA
    Appl Radiat Isot; 2001 Nov; 55(5):667-78. PubMed ID: 11573800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.